HBOT Conversations:
Dr. Peter Canaday (Part 1)
Dr. Peter Canaday has published work in Applied Physiology, Respiratory Medicine, and Diagnostic Radiology. He has presented at National (USA) and International meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on National, State, and Local advisory committees, and given testimony at the State Legislative level in the USA.
Dr. Canaday’s experience with Hyperbaric Oxygen Therapy dates back to the 1980s when he studied HBOT under Dr. Eric Kindwall, “The Father of Hyperbaric Medicine”. Dr. Canaday also co-founded the Hyperbaric Medicine Department at St. Anthony Hospital in Lakewood, Colorado.
From 2007, Dr. Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at a Midlands region DHB and served as Head of Department before retiring in March 2021.
Watch the Podcast
HBOT News welcomes Dr. Peter Canaday. Dr. Canaday now lives primarily in New Zealand, but his history with medicine and Hyperbaric Oxygen Therapy dates back over 40 years to the United States.
In this HBOT News Network Conversations, Dr. Canaday spends the first several minutes providing listeners with his biography and medical background. He also dives into his experience with Hyperbaric Oxygen Therapy in the 1980s.
The subject of PTSD and recent Hyperbaric research arises, and Dr. Canaday expands on the topic by referencing two research articles from Dr. Paul G. Harch –
Dr. Canaday further explains, “There is a recruitment of the anti-inflammatory enzymes and a suppression of the pro-inflammatory enzymes that can be achieved through even these lower pressure units. And so we’re beginning to see now the potential mechanism for which Hyperbaric Therapy, whether with or without oxygen, may be effective.”
The remainder of this HBOT News Conversation is specific to the topic of COVID-19. di Girolamo starts the conversation discussing the struggles for long-hauler COVID patients and the growing number of vaccine injuries as a result of the COVID-19 vaccine. Dr. Canaday agrees that the scientific inquiry for COVID-19 and the available information for associated vaccines has been widely suppressed. He continues that even the data which represent conclusions from peer-reviewed literature has been simply ignored, or set aside without discussion.
In response, Dr. Canaday provides viewers with direct links on how they can learn more about some of the data and information he’s shared with the public regarding the COVID-19 vaccine roll-outs:
Dr Peter Canaday – Pfizer Vaccine Discussion At The Town Hall
Courageous Convos with Special Guest Peter Canaday
Voices of Freedom on Odysee : search Peter Canaday
Dr. Canaday’s HBOT News Conversations is a two part series. Part 2 will air on Friday, December 16, 2022.
This HBOT News Conversation was filmed on October 4, 2022
Guest
Dr. Peter Canaday
Following completion of medical school at the University of Massachusetts in 1976, Dr. Peter Canaday took up training as an Internal Medicine specialist at the University of Michigan, followed by sub-specialist training in Respiratory and Intensive Care at the University of North Carolina. He began his medical career in a busy trauma hospital in Denver, Colorado in 1981 and practiced for 12 years. During his time there, he managed many of the types of patients now seen with severe COVID-19, co-founded a sleep disorders laboratory and a hyperbaric medicine department. As well, he participated in a dozen committee assignments, and rose to Chairman of the Department of Internal Medicine. In 1993, Dr Canaday changed career and completed training as a Radiologist at the University of Wisconsin in 1997. During an 8-year period at Creighton University Medical School in Nebraska, he became tenured as an Assistant Professor of Radiology, and head of the section of Pulmonary Radiology. He also served on or chaired over a dozen hospital and medical school committees and was appointed Clinical Coordinator for the Radiology Department during his time there. Dr Canaday has also published work in applied physiology, respiratory medicine, and diagnostic radiology, has presented at national (USA) and international meetings, and his research supported the eventual FDA approval of a new medical imaging device incorporating digital X-ray tomosynthesis. He has sat on national, state, and local level advisory committees and given testimony at the state legislative level in the USA. From 2007, Dr Canaday spent time in community radiology practices before settling in New Zealand in 2013 as a Consultant Radiologist. Since 2016, he was employed at the Taranaki District Health Board and served as Head of Department before retiring in March 2021.
Subscribe Now, It’s Free!
Recent HBOT News
Clinical Trial – Hyperbaric Oxygenation in Athletes: Standard Versus Low Pressure
Currently, Hyperbaric Oxigen (HBO) is a widely used treatment for several conditions. There
are 14 indications for HBO, officially recognized by the Undersea and Hyperbaric Medical
Society (UHMS), but research is discovering other interesting applications.
HBO plays an important role in enhancing antioxidant defense mechanisms by increasing radical
oxygen species (ROS) and nitric oxide species (NOS). This controlled oxidative stress has
been shown to stop the vicious circle of inflammation – damage – hypoxia already seen in
several diseases. Increased neoangiogenesis has been demonstrated at pressures of 2
atmospheres absolute (ATA), while effects helping ischemic tissues need pressures between 2.5
and 2.8 ATA to develop.
During sports activities, metabolism generates waste products – mostly CO2, lactic acid, but
also ROS. HBO could be useful in modulating antioxidant mechanisms and helping cells in the
recovery after training and sportive competitions.
The authors hypothesize that:
1. HBO can reduce oxidative stress in healthy professional athletes
2. HBO can ameliorate the lactic acid clearance after a maximal exercise
3. HBO at low pressures (L-HBO at 1.45 ATA) is at least comparable to conventional HBO (at
2.5 ATA) in reducing oxidative stress and ameliorating lactic acid clearance after a
maximal exercise.
The Authors will include healthy athletes. These will be randomly assigned to a control
group, a L-HBO group, or a HBO group. The Authors will assess oxidative stress changes and
lactic acid clearance (testing it after a maximal exercise) before and after 20 L-HBO/HBO
treatments, and after 2 months after the end of treatments.
Clinical Trial – Hyperbaric Oxygen Therapy Compared to Pharmaceutical in Fibromyalgia With Emotional Trauma
The investigators have previously studied the efficacy of hyperbaric oxygen therapy (HBOT) as
a treatment for Fibromyalgia syndrome (FMS) in a prospective, active control, crossover
clinical trial. The results demonstrated significant amelioration of all FMS symptoms, with
significant improvement in life quality; furthermore, the investigators were able to
demonstrate significant neuroplasticity on SPECT imaging, with a decrease of the
hyperactivity in posterior regions and elevation of the reduced activity in frontal areas.
In this study, the investigators intend to both repeat and expand the investigator’s previous
findings, treating FMS patients with history of emotional trauma with HBOT, while performing
an extensive of evaluation both before and after treatment.
In the current study, the investigators plan to compare HBOT to current standard of care of
FMS (pharmacological and non – pharmacological).
Hyperbaric Oxygen Therapy gets Lincoln CPA back in business for tax season
17 years ago Tom Shotkoski was diagnosed with colorectal cancer. But, when his surgical site became infected, Shotsoski was left with a life of debilitating pain that restricted him from even being able to sit. His doctors recommended Hyperbaric Oxygen Therapy to...